Diabetic Pharmacotherapy and Endometrial Cancer Risk Within a Publicly Funded Health Care System.

[1]  R. Cobin,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[2]  C. Tseng.  Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan. , 2015, Gynecologic oncology.

[3]  J. Ioannidis,et al.  Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies , 2015, BMJ : British Medical Journal.

[4]  L. Kuller,et al.  Association between diabetes, diabetes treatment and risk of developing endometrial cancer , 2014, British Journal of Cancer.

[5]  T. Stürmer,et al.  Metformin and the risk of endometrial cancer: a population-based cohort study. , 2014, Gynecologic oncology.

[6]  Travis L. Rodkey,et al.  Another Surprise from Metformin: Novel Mechanism of Action via K-Ras Influences Endometrial Cancer Response to Therapy , 2013, Molecular Cancer Therapeutics.

[7]  W. Qi,et al.  Overexpression of the Insulin Receptor Isoform A Promotes Endometrial Carcinoma Cell Growth , 2013, PloS one.

[8]  R. Broaddus,et al.  Chemopreventive effects of metformin on obesity-associated endometrial proliferation. , 2013, American journal of obstetrics and gynecology.

[9]  S. Jick,et al.  Metformin and the risk of endometrial cancer: a case-control analysis. , 2013, Gynecologic oncology.

[10]  T. Rohan,et al.  A Prospective Study of Inflammation Markers and Endometrial Cancer Risk in Postmenopausal Hormone Nonusers , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[11]  E. Gale,et al.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes , 2009, Diabetologia.

[12]  Samy I McFarlane.  Antidiabetic medications and weight gain: Implications for the practicing physician , 2009, Current diabetes reports.

[13]  A. Donker,et al.  Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. , 2009, Archives of internal medicine.

[14]  A. Thor,et al.  Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro , 2009, Cell cycle.

[15]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[16]  Samy Suissa,et al.  Immortal time bias in pharmaco-epidemiology. , 2008, American journal of epidemiology.

[17]  Samy Suissa,et al.  Immortal time bias in observational studies of drug effects , 2007, Pharmacoepidemiology and drug safety.

[18]  C. Mantzoros,et al.  Diabetes and Risk of Endometrial Cancer: A Population-Based Prospective Cohort Study , 2007, Cancer Epidemiology Biomarkers & Prevention.

[19]  S. Majumdar,et al.  Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin , 2006, Diabetes Care.

[20]  R. DePinho,et al.  The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin , 2005, Science.

[21]  R. Kaaks,et al.  Obesity , Endogenous Hormones , and Endometrial Cancer Risk : A Synthetic Review 1 , 2002 .

[22]  T. Sellers,et al.  Diabetes and endometrial cancer in the Iowa women's health study. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[23]  R. Misbin.  Phenformin-associated lactic acidosis: pathogenesis and treatment. , 1977, Annals of internal medicine.